ADC / XDC

Delve into the world of ADC / XDC in China’s pharmaceutical industry. Fineline Info & Tech provides reliable data, news, and insights on ADC / XDC to help you navigate complexities with precision and clarity. Stay informed and enhance your decision-making at flcube.com.

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones
CompanyDeals

Qyuns Therapeutics Out‑Licenses TL1A × IL‑17 Bispecific Program to Caldera Therapeutics – USD 30 Million Upfront with Up to USD 750 Million in Milestones

Qyuns Therapeutics (HKG: 2509) announced that it has entered into an out‑license agreement with Caldera Therapeutics, Inc. covering a preclinical‑stage bispecific antibody program targeting TL1A and IL‑17 (specifically IL‑17A and…

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes

Zai Lab Reports Q3 2026 Revenue of USD 108.2 Million – Nuzyra and New Launches Offset Optune Decline as USD 250 Million ADS Private Placement Closes

Astellas Posts Q2 FY2026 Revenue of JPY 1,270.9 Billion, Up 23.4% – Xtandi and Padcev Lead Surge in Core Operating Profit to JPY 424.9 Billion

Astellas Posts Q2 FY2026 Revenue of JPY 1,270.9 Billion, Up 23.4% – Xtandi and Padcev Lead Surge in Core Operating Profit to JPY 424.9 Billion

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
CompanyDrug

Alphamab Oncology Initiates Phase II Trial of Subcutaneous Co-Formulation JSKN033 in First-Line Advanced Cervical Cancer

CompanyDrug

Sichuan Biokin’s Bispecific ADC Iza-Bren Receives NMPA Approval for NSCLC Clinical Study in China

CompanyDrug

Zai Lab Secures FDA Fast Track Designation for DLL3-Targeting ADC Zocilurtatug Pelitecan in Extrapulmonary NEC

CompanyDrug

CSPC Pharmaceutical Secures Second Breakthrough Therapy Designation for EGFR-Targeting ADC SYS 6010 in Esophageal Cancer

CompanyDrug

Kelun-Biotech Submits New NMPA Filing for Jaitailai in First-Line NSCLC Combination Therapy with Keytruda

CompanyDrug

Simcere Pharmaceutical Receives NMPA Clinical Trial Approval for LRRC15-Targeting ADC SIM0613, Backed by $1.06B Ipsen Global Licensing Deal

CompanyDrug

Hansoh Pharmaceutical’s B7-H3 ADC HS-20093 Receives China BTD for Advanced Prostate Cancer

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million
CompanyDeals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Show More